Moderna (MRNA) PT Raised to $35 at Needham & Company, Following Earnings
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $63.32 -0.52%
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company analyst Alan Carr raised the price target on Moderna (NASDAQ: MRNA) to $35.00 (from $28.00) while maintaining a Hold rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Needham Reiterates Buy Rating on Harmonic Inc. (HLIT)
- Needham Reiterates Buy Rating on WhiteFiber Inc (WYFI)
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & Company, Earnings, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
